References UK clinical guidance from the NHS, the British HIV Association (BHIVA), and the British Association for Sexual Health and HIV (BASHH). Last updated: April 2026.
Non-Hodgkin lymphoma (NHL) is a cancer that starts in the lymphatic system. It is more common in people living with HIV than in the general population, and is classed as an AIDS-defining illness when it occurs at low CD4 counts. With effective HIV treatment the risk has fallen significantly, but NHL remains one of the more important cancers to be aware of.
Here’s what you need to know about the link, the symptoms and the outlook.
Order a discreet home HIV test
Why Is NHL More Common in People with HIV?
Several factors contribute:
- Chronic immune activation, even on effective ART
- Reduced immune surveillance of abnormal cells
- Co-infection with Epstein-Barr virus (EBV), which is linked to some types of NHL
- Past periods of very low CD4 count
Starting ART promptly and maintaining an undetectable viral load lowers the risk substantially, especially for the most aggressive forms.
Types of NHL Seen in HIV
| Type | Notes |
|---|---|
| Diffuse large B-cell lymphoma (DLBCL) | Most common in HIV |
| Burkitt lymphoma | Can occur at higher CD4 counts |
| Primary CNS lymphoma | Usually only in advanced HIV (CD4 < 50) |
| Plasmablastic lymphoma | Rare, more common in HIV |
Symptoms to Watch For
- Painless swollen lymph nodes (neck, armpit, groin)
- Unexplained weight loss
- Drenching night sweats
- Persistent fever
- Unusual fatigue
- Itching without a rash
- A lump or swelling in the abdomen
- Shortness of breath
Any of these symptoms lasting more than a few weeks should be investigated. They can have many causes, most of which are not cancer, but early diagnosis matters if lymphoma is the reason.
How Is It Diagnosed?
Diagnosis usually involves a biopsy of a swollen lymph node. Imaging (CT or PET-CT), blood tests, and sometimes a bone marrow biopsy help to work out the type and how far it has spread.
Treatment
Treatment is usually chemotherapy, often combined with the antibody drug rituximab. People with HIV are treated with the same protocols as people without HIV wherever possible. ART is continued throughout treatment. Outcomes for HIV-positive patients with NHL have improved dramatically in the era of effective HIV treatment.
How to Lower Your Risk
- Stay on ART and keep your viral load undetectable
- Don’t miss HIV clinic appointments
- Report new lumps or persistent symptoms promptly
- Stop smoking
- Limit alcohol
Read more: Cancer and HIV | HIV and the immune system | What is HIV?
Frequently Asked Questions
Does HIV treatment reduce lymphoma risk?
Yes. Effective ART has dramatically reduced the rate of HIV-related lymphomas, particularly the most aggressive types seen in advanced disease.
Are outcomes worse for people with HIV?
In the modern treatment era, outcomes for HIV-positive people with NHL are approaching those of HIV-negative people, especially when ART is continued alongside lymphoma treatment.
What’s the difference between AIDS-defining and non-AIDS-defining lymphoma?
Certain types (like primary CNS lymphoma and some B-cell lymphomas occurring at low CD4 counts) are classed as AIDS-defining. Others occur across all CD4 levels and are not AIDS-defining, but are still more common in people with HIV.
Related reading
- A to Z of Sex: Sexual Health Terms Explained
- Alcohol and HIV: What You Need to Know
- Anxiety and HIV: Coping and Getting Support
- Are All STIs Curable?
- Blood Problems and HIV: Anaemia, Low Platelets and More
Sources
- NHS — Sexual health conditions
- BASHH — UK clinical guidelines for STI management
- British HIV Association (BHIVA) — HIV treatment guidelines
- Terrence Higgins Trust — sexual health information
- UK Health Security Agency — STI surveillance data
Steve Page is a recognised expert on Sexually Transmitted Diseases (STDs) and STD treatments, having published numerous articles in peer-reviewed journals and presented his research at conferences around the world. He has an in-depth understanding of the latest medical research on STDs, and is an advocate for the development of new treatments and protocols to improve the health of those affected. In addition to his research, he has dedicated his career to understanding the causes and symptoms of STDs, as well as how to best treat those impacted.
